Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.

In April, a Securities and Exchange Commission filing revealed that Wojcicki planned to take the company private. 23andMe’s stock price had fallen below $1 per share at the time, down from its $10 ...

Merit predicts the portfolio, which includes devices used in procedures to remove or replace heart rhythm device leads, will add $40 million a year to its sales.

Diagnostic errors were involved in about one out of three adverse patient safety events analyzed in a new report from ECRI and the Institute for Safe Medication Practices PSO. Among the diagnostic ...

Koffey was elected to Masimo’s board in June 2023 along with Politan-backed candidate Michelle Brennan, a former Johnson & Johnson executive. The hedge fund argued that Masimo’s $1 billion acquisition ...

The patient can use his implant to turn on lights, make video calls, play music and shows, read books and buy products online without using his hands or voice.

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

With the rise of interest around AI since the release of large language models (LLMs), there is pressure on MedTech executives to get ahead of industry peers regarding AI, not only within devices but ...

The FDA posted a second Smiths recall on Wednesday related to a problem with certain ParaPac ventilator kits. A knob that sets the tidal volume, or the amount of air delivered with each breath, can ...

Senseonics and commercial partner Ascensia Diabetes Care received clearance from the Food and Drug Administration for the first implantable glucose sensor that can be worn for one year, doubling the ...

Boston Scientific and Silk Road announced the merger in June. The deal valued Silk Road at $27.50 per share. Silk Road manufacturers devices used in a minimally invasive procedure called transcarotid ...

Apple applied for de novo authorization in December. The company validated the technology in a study that enrolled 118 people with perceived mild to moderate hearing loss at multiple U.S. sites.